{"nctId":"NCT03338023","briefTitle":"A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus","startDateStruct":{"date":"2018-03-23","type":"ACTUAL"},"conditions":["Type 1 Diabetes"],"count":272,"armGroups":[{"label":"LY2963016 + Insulin Lispro","type":"EXPERIMENTAL","interventionNames":["Drug: LY2963016","Drug: Insulin Lispro"]},{"label":"Lantus® + Insulin Lispro","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Lantus®","Drug: Insulin Lispro"]}],"interventions":[{"name":"LY2963016","otherNames":[]},{"name":"Lantus®","otherNames":[]},{"name":"Insulin Lispro","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have T1DM based on the disease diagnostic criteria (World Health Organization \\[WHO\\] Classification).\n* Have duration of T1DM ≥1 year.\n* Have HbA1c ≤11 %.\n* Have been administered with basal-bolus insulins or pre-mixed insulins for at least 90 days prior to screening.\n* Have a body mass index (BMI) ≤35 kilograms per meter squared.\n\nExclusion Criteria:\n\n* Exposure to an insulin glargine other than Lantus® within previous 30 days.\n* Have had more than one episode of severe hypoglycemia within 6 months prior to entry into the study.\n* Have had more than one episode of diabetic ketoacidosis or emergency room visits for uncontrolled diabetes leading to hospitalization within 6 months prior to entry into the study.\n* Have known hypersensitivity or allergy to any of the study insulins (Lantus® or insulin lispro) or to excipients of the study insulins.\n* Are pregnant, intend to become pregnant during the course of the study.\n* Women who are breastfeeding.\n* Are currently taking traditional medicine (herbal medicine or patent medicine) with known/specified content of anti-hyperglycemic effects within 3 months before screening.\n* Have congestive heart failure Class III and IV.\n* Have obvious clinical signs or symptoms, or laboratory evidence, of liver disease.\n* Have any active cancer.\n* Have a history or diagnosis of human immunodeficiency virus (HIV) infection.\n* Have presence of clinically significant gastrointestinal disease.\n* Have a history of renal transplantation, or are currently receiving renal dialysis.\n* Are receiving chronic systemic glucocorticoid therapy at pharmacological doses.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (HbA1c) (LY2963016 Noninferior to Lantus®)","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least square (LS) mean was calculated using mixed-effects model for repeated measures (MMRM) with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\\*Treatment (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.071"},{"groupId":"OG001","value":"-0.08","spread":"0.071"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in HbA1c (Lantus® Noninferior to LY2963016)","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. LS mean was calculated using MMRM with variables baseline HbA1c + Treatment + Pre-study treatment + Pre-study metformin or acarbose usage + Time + Time\\*Treatment (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.20","spread":"0.071"},{"groupId":"OG001","value":"-0.08","spread":"0.071"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 7-Point Self-Monitored Blood Glucose (SMBG) Values","description":"The self-monitored plasma glucose (SMBG) data were collected at the following 7 time points: Before Morning Meal Glucose, 2 Hours After Morning Meal Glucose, Before Mid-Day Meal Glucose, 2 Hours After Mid-Day Meal Glucose, Before Evening Meal Glucose, Bedtime Glucose and 0300 Am Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.2","spread":"3.64"},{"groupId":"OG001","value":"-0.4","spread":"3.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"4.77"},{"groupId":"OG001","value":"-2.8","spread":"4.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.6","spread":"4.13"},{"groupId":"OG001","value":"8.5","spread":"4.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"4.76"},{"groupId":"OG001","value":"1.9","spread":"4.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.2","spread":"4.78"},{"groupId":"OG001","value":"4.8","spread":"4.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"4.99"},{"groupId":"OG001","value":"5.0","spread":"5.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.9","spread":"3.87"},{"groupId":"OG001","value":"2.5","spread":"3.94"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c <7%","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":null},{"groupId":"OG001","value":"32.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With HbA1c ≤6.5%","description":"HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"22.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Intrapatient Blood Glucose (BG) Variability, Measured by the Standard Deviation of 7-point SMBG","description":"Change From Baseline in Intrapatient blood glucose (BG). LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.9","spread":"1.33"},{"groupId":"OG001","value":"-2.6","spread":"1.34"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Glycemic Variability of Fasting Blood Glucose","description":"Change From Baseline in Glycemic Variability of Fasting Blood Glucose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"2.53"},{"groupId":"OG001","value":"-5.5","spread":"2.56"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.4","spread":"1.69"},{"groupId":"OG001","value":"-8.6","spread":"1.71"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Basal Insulin Dose","description":"Change from baseline in basal insulin dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.33"},{"groupId":"OG001","value":"1.5","spread":"0.33"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Prandial Insulin Dose","description":"Prandial Insulin Dose. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.49"},{"groupId":"OG001","value":"1.4","spread":"0.50"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Body Weight","description":"Change from baseline in body weight. LS mean was calculated using MMRM with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Actual Measurement) = Unstructured. Variance-Covariance structure (Change from Baseline) = Unstructured.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.21"},{"groupId":"OG001","value":"0.9","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Insulin Treatment Satisfaction Questionnaire (ITSQ)","description":"The ITSQ is a validated 22-item questionnaire that was used to assess treatment satisfaction. Items were measured on a 7-point scale, with lower scores reflecting better outcomes. In addition to an overall score, scores were also obtained for 5 domains, including inconvenience of regimen, lifestyle flexibility, glycemic control, hypoglycemic control, and insulin delivery device. Raw domain and overall scores were transformed on a scale from 0 to 100, where a higher score indicated better treatment satisfaction.\n\nLS mean was calculated using ANCOVA with variables Baseline + Pre-study Treatment + Pre-study Metformin or Acarbose Usage + HbA1c at Baseline + Treatment (Type III sum of squares).","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.5","spread":"1.30"},{"groupId":"OG001","value":"3.8","spread":"1.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.86"},{"groupId":"OG001","value":"2.0","spread":"1.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"1.39"},{"groupId":"OG001","value":"3.8","spread":"1.38"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.9","spread":"1.64"},{"groupId":"OG001","value":"6.0","spread":"1.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.26"},{"groupId":"OG001","value":"2.9","spread":"1.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"1.10"},{"groupId":"OG001","value":"4.1","spread":"1.10"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Detectable Anti-Glargine Antibodies","description":"Number of participants with detectable anti-glargine antibodies","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"76","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Documented Symptomatic Hypoglycemia","description":"Hypoglycemic episodes are defined as events that are associated with reported signs and symptoms of hypoglycemia and/or documented blood glucose (BG) concentrations of ≤70 mg/dL (3.9 mmol/L). The overall yearly rates (events/participant/year) of those hypoglycemic events, calculated as, for each participant, the number of episodes times 365.25 and then divided by the participants treatment duration, will be summarized, and analyzed by a Negative-binomial regression model with treatment as fixed effects and log of (patient's treatment duration/365.25) as an offset variable.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.6","spread":"2.42"},{"groupId":"OG001","value":"14.0","spread":"2.64"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":9,"n":137},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Injection site pain","Diarrhoea","Toothache"]}}}